• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

作者信息

Baye Jordan

出版信息

P T. 2012 Mar;37(3):149-61.

PMID:22605906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3351880/
Abstract
摘要

相似文献

1
Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.罗氟司特（达力新）：一种用于治疗重度慢性阻塞性肺疾病的新型磷酸二酯酶-4抑制剂。
P T. 2012 Mar;37(3):149-61.
2
Roflumilast: A Review in COPD.罗氟司特：在 COPD 中的应用评价。
Drugs. 2015 Sep;75(14):1645-56. doi: 10.1007/s40265-015-0463-1.
3
Roflumilast in the management of chronic obstructive pulmonary disease.罗氟司特在慢性阻塞性肺疾病管理中的应用。
Am J Health Syst Pharm. 2013 Dec 1;70(23):2087-95. doi: 10.2146/ajhp130114.
4
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.罗氟司特：首个获批用于治疗慢性阻塞性肺疾病的磷酸二酯酶4抑制剂。
Drug Des Devel Ther. 2010 Jul 21;4:147-58. doi: 10.2147/dddt.s7667.
5
The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.罗氟司特的临床前药理学——一种用于慢性阻塞性肺疾病的选择性、口服磷酸二酯酶 4 抑制剂。
Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7.
6
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.罗氟司特对联合治疗控制不佳的重度慢性阻塞性肺疾病患者加重的影响（REACT）：一项多中心随机对照试验。
Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13.
7
Roflumilast (Daliresp) for COPD.罗氟司特（达力释）用于慢性阻塞性肺疾病。
Med Lett Drugs Ther. 2011 Jul 25;53(1369):59-60.
8
Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.磷酸二酯酶 4 抑制剂增强了福莫特罗增强糖皮质激素依赖性基因转录在人呼吸道上皮细胞中的能力：罗氟司特在严重慢性阻塞性肺疾病中临床疗效的新机制。
Mol Pharmacol. 2013 Apr;83(4):894-906. doi: 10.1124/mol.112.083493. Epub 2013 Feb 6.
9
Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory study.罗氟司特对糖尿病前期及超重/肥胖成年人胰岛素敏感性的早期影响涉及与年龄相关的脂肪量减少——一项探索性研究的结果
Diabetes Metab Syndr Obes. 2019 May 27;12:743-759. doi: 10.2147/DMSO.S182953. eCollection 2019.
10
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.罗氟司特：一种磷酸二酯酶-4 抑制剂，用于治疗严重的慢性阻塞性肺疾病。
Clin Ther. 2012 Jan;34(1):56-66. doi: 10.1016/j.clinthera.2011.12.008.

引用本文的文献

1
Treating chronic obstructive pulmonary disease with ensifentrine: a systematic review.恩昔芬净治疗慢性阻塞性肺疾病的系统评价
Front Med (Lausanne). 2025 Sep 5;12:1595662. doi: 10.3389/fmed.2025.1595662. eCollection 2025.
2
Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology.探索治疗领域：关于皮肤科局部和口服磷酸二酯酶-4抑制剂的叙述性综述
Pharmaceutics. 2025 Jan 12;17(1):91. doi: 10.3390/pharmaceutics17010091.
3
Topical Application of Dipyridamole and Roflumilast Combination Nanoparticles Loaded Nanoemulgel for the Treatment of Psoriasis in Rats.双嘧达莫与罗氟司特组合纳米粒负载纳米乳凝胶局部应用于大鼠银屑病的治疗
Int J Nanomedicine. 2024 Dec 7;19:13113-13134. doi: 10.2147/IJN.S492180. eCollection 2024.
4
Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.化脓性汗腺炎：生物制剂和小分子免疫调节治疗综述
J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.
5
Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study.罗氟司特治疗慢性阻塞性肺疾病患者的长期安全性：一项多国观察性数据库队列研究。
Int J Chron Obstruct Pulmon Dis. 2024 Aug 21;19:1879-1892. doi: 10.2147/COPD.S465517. eCollection 2024.
6
Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer.罗氟司特抑制STK11/LKB1缺陷型胰腺癌的肿瘤生长和迁移。
Cell Death Discov. 2024 Mar 9;10(1):124. doi: 10.1038/s41420-024-01890-y.
7
A four-part guide to lung immunology: Invasion, inflammation, immunity, and intervention.肺免疫学四步曲：入侵、炎症、免疫与干预。
Front Immunol. 2023 Mar 31;14:1119564. doi: 10.3389/fimmu.2023.1119564. eCollection 2023.
8
Investigation of apoptotic and autophagic effects of chronic roflumilast use on testicular tissue in rats by immunohistochemical and immunofluorescence methods.通过免疫组织化学和免疫荧光方法研究长期使用罗氟司特对大鼠睾丸组织的凋亡和自噬作用。
Iran J Basic Med Sci. 2023 Mar;26(3):276-284. doi: 10.22038/IJBMS.2023.65948.14507.
9
Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.罗氟司特乳膏在慢性斑块型银屑病中的药代动力学：来自 I 期至 III 期研究的数据。
Am J Clin Dermatol. 2023 Mar;24(2):315-324. doi: 10.1007/s40257-022-00741-9. Epub 2022 Nov 24.
10
An inhibitor of RORγ for chronic pulmonary obstructive disease treatment.一种用于治疗慢性阻塞性肺疾病的 RORγ 抑制剂。
Sci Rep. 2022 May 24;12(1):8744. doi: 10.1038/s41598-022-12251-z.

本文引用的文献

1
Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.肾功能损害对口服罗氟司特药代动力学的影响：一项开放标签、平行组、单中心研究。
Int J Clin Pharmacol Ther. 2011 Aug;49(8):491-9. doi: 10.5414/cp201556.
2
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病的磷酸二酯酶4抑制剂
Cochrane Database Syst Rev. 2011 May 11(5):CD002309. doi: 10.1002/14651858.CD002309.pub3.
3
High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast.新型口服磷酸二酯酶-4抑制剂罗氟司特具有高绝对生物利用度。
Int J Clin Pharmacol Ther. 2011 Jan;49(1):51-7. doi: 10.5414/cpp49051.
4
Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.利福平对健康受试者中罗氟司特及其 N-氧化物药代动力学的影响。
Br J Clin Pharmacol. 2009 Oct;68(4):580-7. doi: 10.1111/j.1365-2125.2009.03478.x.
5
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.罗氟司特用于长效支气管扩张剂治疗的中重度慢性阻塞性肺疾病：两项随机临床试验
Lancet. 2009 Aug 29;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6.
6
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.罗氟司特治疗有症状的慢性阻塞性肺疾病：两项随机临床试验
Lancet. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1.
7
Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.重复剂量红霉素对罗氟司特及罗氟司特N-氧化物药代动力学的影响。
Int J Clin Pharmacol Ther. 2009 Apr;47(4):236-45. doi: 10.5414/cpp47236.
8
The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.靶向口服的每日一次磷酸二酯酶4抑制剂罗氟司特与白三烯受体拮抗剂孟鲁司特未表现出显著的药代动力学相互作用。
J Clin Pharmacol. 2009 Apr;49(4):389-97. doi: 10.1177/0091270008330980.
9
Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.单次及重复剂量酮康唑对罗氟司特及其N-氧化物药代动力学的影响。
J Clin Pharmacol. 2008 Nov;48(11):1339-49. doi: 10.1177/0091270008321941. Epub 2008 Aug 29.
10
Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial.罗氟司特减轻健康受试者节段性内毒素激发后的肺部炎症：一项随机安慰剂对照试验。
Pulm Pharmacol Ther. 2008 Aug;21(4):616-23. doi: 10.1016/j.pupt.2008.02.002. Epub 2008 Feb 21.